Regenerative medicine industry seeks to define cost-effectiveness on its own terms

7 August 2018
2019_biotech_test_vial_discovery_big

The industry-funded ARM Foundation for Cell and Gene Medicine has launched a new health economic analysis of regenerative medicine therapies, which includes a review of academic literature, health technology assessments, and value frameworks.

The so-called ‘ landscape assessment,’ which was performed by industry analyst IQVIA on behalf of the Foundation, is intended as a first step towards a new cost-effectiveness methodology for regenerative medicines.

Such a framework could be used to rival assessments provided by the Institute for Clinical and Economic Review (ICER), a group that is  perceived as providing more payer-friendly analyses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology